Premaitha Health PLC, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) confirms that Chief Medical Officer, Dr William Denman, will join the Board of Premaitha as an Executive Director on 1 November 2015.
Dr Denman has been working with Premaitha for over four years. This appointment will further strengthen the Board and is a continued part of the Company’s commercialisation strategy, said the company in announcemen issued on Wednesday.
Dr Denman has significant experience in the clinical aspects of device and diagnostic development having specialised in paediatric anaesthesia and medical device development at Massachusetts General Hospital. Previously, he was CMO with GE Healthcare with primary responsibility for all matters of patient safety in this multi-billion dollar business. He has also been responsible for strategic direction of medical affairs, clinical affairs and healthcare economics and outcomes across Covidien plc’s medical device business. Dr Denman studied medicine at the University of Aberdeen.
David Evans, Chairman of Premaitha commented:
“Over the last four years, we’ve developed a great partnership with William. He has helped build strong relationships between Premaitha and some of the key opinion leaders in NIPT, putting us at the forefront of this nascent sector. His impressive experience and track record will further strengthen our Board and management team as we continue to ramp-up our commercialisation strategy.”